DLBCL Clinical Trials in Beijing, Beijing Municipality
10 recruitingBeijing, Beijing Municipality, China
Showing 1–10 of 10 trials
Recruiting
Phase 2Phase 3
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
Diffuse Large B Cell LymphomaDLBCL
Merck Sharp & Dohme LLC290 enrolled132 locationsNCT05139017
Recruiting
Phase 1Phase 2
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
Non-Hodgkin LymphomaMantle Cell LymphomaFollicular Lymphoma+6 more
BeiGene146 enrolled29 locationsNCT05294731
Recruiting
Phase 2
Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma (DLBCL)Primary Central Nervous System Lymphoma (PCNSL)
Beijing Tongren Hospital43 enrolled1 locationNCT07523737
Recruiting
Glofitamab in Chinese Patients With R/R DLBCL
DLBCL - Diffuse Large B Cell Lymphoma
Peking Union Medical College Hospital20 enrolled1 locationNCT06481826
Recruiting
Phase 2
Enhancing CAR-T Cell Therapy Efficacy in B-cell Lymphoma Via Chidamide and PD-1 Inhibitor Combination.
Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
Daihong Liu30 enrolled1 locationNCT07489989
Recruiting
Phase 1Phase 2
Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
Breast CancerLiver CancerNon-small Cell Lung Cancer (NSCLC)+10 more
Essen Biotech85 enrolled1 locationNCT07410494
Recruiting
Phase 2
Application of Zanubrutinib-based Combination Regimens in the Treatment of Newly-diagnosed Diffuse Large B-cell Lymphoma
Diffuse Large B-Cell Lymphoma (DLBCL)
Beijing Tongren Hospital50 enrolled1 locationNCT07371923
Recruiting
Phase 2
A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma (DLBCL)
Guangzhou Lupeng Pharmaceutical Company LTD.150 enrolled41 locationsNCT07189065
Recruiting
Phase 1Phase 2
A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma (DLBCL)
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.97 enrolled21 locationsNCT07124936
Recruiting
Phase 1Phase 2
A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)
Advanced Solid TumorDLBCL
Ranok Therapeutics (Hangzhou) Co., Ltd.32 enrolled5 locationsNCT05487170